priors.science/reviews/ovarian-cancer-pharmacotherapy

Ovarian Cancer Pharmacotherapy

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
30 May 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 10 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableCarboplatin and paclitaxel as standard first-line ovarian therapyPlatEstablished92%8
StableBRCA mutation predicts PARP inhibitor benefit in ovarian cancerBioEstablished90%8
StableOlaparib first-line maintenance progression-free survival in BRCA-mutant diseasePARP FLEstablished88%9
StableOlaparib recurrent-disease maintenance progression-free survivalPARP RecEstablished86%8
StableBevacizumab progression-free survival in platinum-sensitive recurrent diseaseBevEstablished85%8
StablePD-1 single-agent limited activity in ovarian cancerIoEstablished85%8
StableNiraparib first-line maintenance progression-free survival in all-comersPARP FLEstablished85%8
StableBevacizumab maintenance progression-free survival in first-line therapyBevLikely84%8
StableBevacizumab progression-free survival in platinum-resistant ovarian cancerPlresLikely84%8
StablePegylated liposomal doxorubicin activity in platinum-resistant ovarian cancerPlresLikely82%8
StableHomologous recombination deficiency testing for PARP inhibitor benefit beyond BRCABioLikely74%8
StableOlaparib plus bevacizumab progression-free survival in homologous recombination deficiency-positive diseasePARP FLLikely74%8
StableMirvetuximab overall survival in platinum-resistant ovarian cancerAdcLikely73%8
StableNeoadjuvant chemotherapy non-inferior to primary debulkingSurgLikely72%8
StableWeekly paclitaxel progression-free survival in platinum-resistant diseasePlresLikely70%8
StableFolate receptor alpha expression predicts mirvetuximab benefitAdcLikely68%8
StablePARP inhibitor rechallenge benefit in recurrent ovarian cancerPARP RecLikely67%8
StableDose-dense paclitaxel benefit in ovarian cancerPlatUncertain55%8
StableHyperthermic intraperitoneal chemotherapy at interval debulking, overall survival in ovarian cancerSurgUncertain53%8
StableImmunotherapy and PARP inhibitor combination in ovarian cancerIoUncertain52%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic